NCT02362997 2026-02-12Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHLDana-Farber Cancer InstitutePhase 2 Completed82 enrolled 20 charts
NCT05313243 2025-03-20Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell LymphomaYale UniversityPhase 2 Recruiting32 enrolled